11 – 20 of 27
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2020
-
Mark
A Consensus Molecular Classification of Muscle-invasive Bladder Cancer
(
- Contribution to journal › Article
-
Mark
Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer : A Step in the Right Direction but Still a Long Way To Go.
(
- Contribution to journal › Debate/Note/Editorial
- 2019
-
Mark
Increased use of cross-sectional imaging for follow-up does not improve post-recurrence survival of surgically treated initially localized R.C.C. : results from a European multicenter database (R.E.C.U.R.)
(
- Contribution to journal › Article
-
Mark
Long-term Outcomes of Follow-up for Initially Localised Clear Cell Renal Cell Carcinoma : RECUR Database Analysis
(
- Contribution to journal › Article
-
Mark
European Association of Urology Guidelines on Renal Cell Carcinoma : The 2019 Update
(
- Contribution to journal › Article
-
Mark
Intensive Imaging-based Follow-up of Surgically Treated Localised Renal Cell Carcinoma Does Not Improve Post-recurrence Survival : Results from a European Multicentre Database (RECUR)
(
- Contribution to journal › Letter
- 2018
-
Mark
Updated European Association of Urology Guidelines : Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer
(
- Contribution to journal › Article
-
Mark
Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition : The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations
(
- Contribution to journal › Letter
-
Mark
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
(
- Contribution to journal › Article